U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Search AHRQ

For an exact phrase match, enclose search terms in double quotes.

Go to Advanced Search
Go to Basic Search

Results

Total Results: 4,630 records

Showing results for "tissue".

  1. Evidence-Summary-CER-209-Noninvasive-Nonpharmacological-Treatment-For-Chronic-Pain (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-209-evidence-summary-non-pharma-chronic-pain.pdf
    June 01, 2018 - pain is often defined as pain lasting 3 months or longer or persisting past the normal time for tissue

  2. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review Update - Evidence Summary (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/noninvasive-nonpharm-pain-summary.pdf
    April 01, 2020 - pain is often defined as pain lasting 3 months or longer or persisting past the normal time for tissue

  3. Crosscutting-Horizon-Scan-High-Impact-1512 (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1512.pdf
    December 01, 2015 - The choice of imaging depends on tissue type and location of the region of interest.

  4. Crosscutting-Horizon-Scan-High-Impact-1506 (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1506.pdf
    June 01, 2015 - The types of imaging available include CT, MRI, and ultrasound—the choice of imaging depends on tissue

  5. Evidence-Summary-CER-209-Noninvasive-Nonpharmacological-Treatment-For-Chronic-Pain (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-209-evidence-summary-non-pharma-chronic-pain.pdf
    June 01, 2018 - pain is often defined as pain lasting 3 months or longer or persisting past the normal time for tissue

  6. Management of Infertility | Effective Health Care (EHC) Program

    effectivehealthcare-admin.ahrq.gov/products/infertility/research-protocol
    October 01, 2019 - criteria/evaluation; stage of endometriosis; presence of endometriomia (ovarian cyst with endometrial tissue

  7. Evidence Summary: Breast Cancer: Screening | United States Preventive Services Taskforce

    www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/breast-cancer-screening
    April 30, 2024 - studies using DBT with synthetic digital mammography. 33 , 47 Supplemental Screening The Dense Tissue

  8. Archived: Evidence Summary: Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis | United States Preventive Services Taskforce

    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis-june-2019
    June 11, 2019 - concentrations they accumulate at exposure sites (eg, genital vs rectal mucosa), and the correlation between tissue

  9. Gout Executive (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/gout_executive.pdf
    March 01, 2016 - Tophi may develop in joints, cartilage, bone, and auricular or other cutaneous tissues.5 The average

  10. Gout Executive (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/gout_executive.pdf
    March 01, 2016 - Tophi may develop in joints, cartilage, bone, and auricular or other cutaneous tissues.5 The average

  11. Screening for Elevated Lead Levels in Childhood and Pregnancy: An Updated Summary of Evidence (pdf file)

    www.uspreventiveservicestaskforce.org/home/getfilebytoken/bWme33U4raQYVZzafX8TjL
    August 01, 2005 - mean, random variation, laboratory error, and redistribution of lead from blood to other tissue … regression to the mean, random variation, laboratory error, and redistribution of lead from blood to other tissue

  12. Assessing the Availability of the Preconception Component of High-Risk Obstetrical Services by Estimating the Use of Teratogenic Medications Before and During Pregnancy (pdf file)

    www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/availability/chipra-233-fullreport.pdf
    August 07, 2018 - Additional adverse fetal effects that result in dysfunction of a formed organ or tissue include postnatal

  13. Assessing the Availability of the Preconception Component of High-Risk Obstetrical Services by Estimating the Use of Teratogenic Medications Before and During Pregnancy (pdf file)

    www.monahrq.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/availability/chipra-233-fullreport.pdf
    August 07, 2018 - Additional adverse fetal effects that result in dysfunction of a formed organ or tissue include postnatal

  14. Assessing the Availability of the Preconception Component of High-Risk Obstetrical Services by Estimating the Use of Teratogenic Medications Before and During Pregnancy (pdf file)

    www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/availability/chipra-233-fullreport.pdf
    August 07, 2018 - Additional adverse fetal effects that result in dysfunction of a formed organ or tissue include postnatal

  15. Assessing the Availability of the Preconception Component of High-Risk Obstetrical Services by Estimating the Use of Teratogenic Medications Before and During Pregnancy (pdf file)

    www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/availability/chipra-233-fullreport.pdf
    August 07, 2018 - Additional adverse fetal effects that result in dysfunction of a formed organ or tissue include postnatal

  16. Assessing the Availability of the Preconception Component of High-Risk Obstetrical Services by Estimating the Use of Teratogenic Medications Before and During Pregnancy (pdf file)

    www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/availability/chipra-233-fullreport.pdf
    August 07, 2018 - Additional adverse fetal effects that result in dysfunction of a formed organ or tissue include postnatal

  17. Assessing the Availability of the Preconception Component of High-Risk Obstetrical Services by Estimating the Use of Teratogenic Medications Before and During Pregnancy (pdf file)

    www.cahps.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/availability/chipra-233-fullreport.pdf
    August 07, 2018 - Additional adverse fetal effects that result in dysfunction of a formed organ or tissue include postnatal

  18. Assessing the Availability of the Preconception Component of High-Risk Obstetrical Services by Estimating the Use of Teratogenic Medications Before and During Pregnancy (pdf file)

    ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/availability/chipra-233-fullreport.pdf
    August 07, 2018 - Additional adverse fetal effects that result in dysfunction of a formed organ or tissue include postnatal

  19. Disposition of Comments for CER 196 The Role of Immunotherapy in the Treatment of Asthma (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-196-disposition-comments-immunotherapy-asthma.pdf
    March 23, 2018 - immunotherapy (SCIT) injections are not “into the skin”, as indicated by subcutaneous they are into the fatty tissue

  20. Disposition of Comments for CER 167 Renal Masses (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/renal-cancer_disposition-comments.pdf
    February 24, 2016 - outcomes related to the radiographic appearance of ablated tissue.
SHARE:
Facebook Twitter Print Facebook Share

Similar Terms:

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

Click to show only results for the selected site.

hcup-us.ahrq.gov (811)

effectivehealthcare-admin.ahrq.gov (671)

effectivehealthcare.ahrq.gov (639)

www.ahrq.gov (451)

psnet.ahrq.gov (379)

ce.effectivehealthcare.ahrq.gov (301)

www.uspreventiveservicestaskforce.org (207)

www.qualitymeasures.ahrq.gov (147)

www.cahps.ahrq.gov (78)

www.monahrq.ahrq.gov (77)

www.innovations.ahrq.gov (76)

www.healthcare411.ahrq.gov (75)

www.talkingquality.ahrq.gov (73)

www.cpsi.ahrq.gov (69)

qualityindicators.ahrq.gov (68)

preventiveservices.ahrq.gov (56)

cahps.ahrq.gov (48)

monahrq.ahrq.gov (47)

pbrn.ahrq.gov (47)

healthcare411.ahrq.gov (46)

pcmh.ahrq.gov (43)

talkingquality.ahrq.gov (38)

patientregistry.ahrq.gov (35)

ahrqpubs.ahrq.gov (34)

digital.ahrq.gov (25)

teamstepps.ahrq.gov (25)

srdr.ahrq.gov (24)

meps.ahrq.gov (18)

cds.ahrq.gov (7)

www.psoppc.org (5)

datatools.ahrq.gov (3)

staging-meps.ahrq.gov (3)

pso.ahrq.gov (2)

srdrplus.ahrq.gov (2)